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Normal cell growth requires a precisely controlled balance between cell death and survival. This involves
activation of different types of intracellular signaling cascades within the cell. While some types of signaling
proteins regulate apoptosis, or programmed cell death, other proteins within the cell can promote survival. The
serine/threonine kinase PAK4 can protect cells from apoptosis in response to several different types of stimuli.
As is the case for other members of the p21-activated kinase (PAK) family, one way that PAK4 may promote
cell survival is by phosphorylating and thereby inhibiting the proapoptotic protein Bad. This leads in turn to
the inhibition of effector caspases such as caspase 3. Here we show that in response to cytokines which activate
death domain-containing receptors, such as the tumor necrosis factor and Fas receptors, PAK4 can inhibit the
death signal by a different mechanism. Under these conditions, PAK4 inhibits apoptosis early in the caspase
cascade, antagonizing the activation of initiator caspase 8. This inhibition, which does not require PAK4’s
kinase activity, may involve inhibition of caspase 8 recruitment to the death domain receptors. This role in
regulating initiator caspases is an entirely novel role for the PAK proteins and suggests a new mechanism by
which these proteins promote cell survival.
The balance between apoptosis and survival in a cell is con-
trolled by various intracellular signaling pathways. A number
of different stimuli can trigger apoptosis in cells, including
ligation of death domain receptors such as the Fas receptor or
the tumor necrosis factor alpha (TNF-) receptor (2, 52, 72) or
deprivation of nutrients such as growth factors or serum (56).
Apoptosis is generally mediated by caspase cascades that lead
to cleavage or activation of molecules that are important for
cell death (9, 59, 68). Cell survival pathways can be mediated
by proteins which inhibit the caspase cascades at various stages.
Different types of apoptotic stimuli can trigger cell death by
different mechanisms. Fas ligand and the cytokine TNF-, for
example, bind to cell surface receptors and in turn induce the
activation and cleavage of the initiator caspases, such as cas-
pase 8 and caspase 10. Once activated, caspase 8 can activate
two different apoptotic pathways (27). First, it can directly
cleave and activate effector caspases, such as caspases 3 and 7.
Effector caspases in turn cleave a number of different target
proteins that play important roles in mediating the apoptotic
response (59, 68). Second, caspase 8 can activate a mitochon-
drial pathway which is mediated by the caspase 8 substrate Bid
(29, 43, 45, 76). Once it is cleaved by caspase 8, the truncated
Bid translocates to the mitochondria, where it interacts with
members of the Bcl2 family to promote cytochrome c release.
Release of cytochrome c from the mitochondria leads to acti-
vation of caspase 9 followed by cleavage and activation of
caspase 3, leading to apoptosis (26, 27).
Signaling by cytokine receptors such as the Fas receptor and
the TNF receptor (TNFR) actually starts when the receptors
trimerize following binding by the ligand. The trimerized re-
ceptors recruit a number of proteins through their protein-
protein interaction motifs, and these proteins in turn lead to
activation of the caspase cascades (2, 72). The main docking
protein of TNFR1 is the TNFR-associated death domain pro-
tein (TRADD), which binds to the TNFR via an interaction
between the respective death domains (33). TRADD then
recruits other death domain-containing proteins, including the
Fas-associated protein with death domain (FADD) or recep-
tor-interacting protein (RIP), via its death domain (7, 14, 32,
33, 66). Finally, FADD can recruit caspase 8 to the complex (7,
50), which in turn is cleaved and activated, triggering the
apoptotic response described above. In contrast, RIP, together
with its interacting protein TRAF, signals to the NF-B path-
way which can lead instead to protection from apoptosis (5,
31–33, 44, 65, 78). The major binding partner for the Fas
receptor is FADD, which also binds to the receptor through its
death domain (7, 14). FADD in turn binds directly to caspase
8, which is activated by oligomerization and self-cleavage (6,
49–51). The signaling network that is formed at the death
receptor after stimulation is referred to as the death-inducing
signaling complex (DISC) (41).
Throughout development, excess cells are eliminated by the
process of apoptosis, while other cells are protected from apo-
ptosis by different mechanisms. A number of cell survival path-
ways exist for protecting cells from apoptosis. For example,
NF-B can protect cells from apoptosis by inducing the expres-
sion of genes involved in cell survival (22). Another example of
a protein that can protect cells from apoptosis is the lipid
kinase phosphatidylinositol 3-kinase (PI 3-kinase) (12, 21). PI
3-kinase activity is stimulated by exposure to growth factors or
serum. This leads to activation of the survival protein AKT.
AKT phosphorylates a number of substrates, including the
proapoptotic protein Bad, leading to its inactivation (18).
Phosphorylation of Bad prevents activation of the mitochon-
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drial pathway and cytochrome c release and thereby protects
cells from apoptosis (20). For this reason, many cells are highly
sensitive to serum deprivation and undergo apoptosis when
grown under low-serum conditions.
The p21-activated kinase (PAK) serine/threonine kinases
are a family of protein kinases that may also play a protective
role against apoptosis. The PAK family members were origi-
nally identified as molecular targets for the Rho GTPases Rac
and Cdc42 (1, 4, 8, 10, 47, 48; for reviews, see references 3, 16,
and 63). There are six members of the PAK family in mam-
mals, which fall into two categories (group A and group B)
based on their amino acid sequences and functions (35). The
group A PAKs consist of the closely related PAK1, -2, and -3
(4, 8, 47, 48), whereas the group B PAKs consist of PAK4, -5,
and -6 (1, 15, 53, 75). All of the PAKs contain a GTPase
binding domain, which binds to the Rho GTPases, and a
serine/threonine kinase domain that is similar to the kinase
domain of yeast STE20. The group A and B PAKs are only
approximately 50% identical to each other in the GTPase
binding domain and kinase domain, and they differ completely
throughout the rest of their amino acid sequences (35).
Although they were first identified as proteins that play an
important role in regulating cytoskeletal organization and cell
morphology, the PAKs have also been shown to have impor-
tant roles in regulating the apoptotic response, although their
effects differ under different conditions. For example, PAK2 is
cleaved during Fas-induced apoptosis in T cells, most likely by
caspase 3. This was shown to lead to its activation, leading to
morphological and membrane changes that occur during apo-
ptosis (42, 58, 73). In other studies, however, PAK2 was shown
to protect fibroblasts from apoptosis in response to various
stimuli, including TNF-, serum starvation, and UV irradia-
tion (36). Likewise, PAK1, which is not cleaved during apo-
ptosis, was reported to protect cells from apoptosis induced by
either serum withdrawal in fibroblasts or interleukin-3 with-
drawal in lymphoid cells (62, 67). The survival signal induced
by PAK1 is apparently due to direct phosphorylation of Bad on
both serines 112 and 136 (62, 67). PAK2 may also operate by
phosphorylating Bad, as well as by activating mitogen-activated
protein (MAP) kinase pathways (36).
We have found that PAK4 can also protect cells from apo-
ptosis in response to a number of different stimuli (23). As is
the case for PAK1, one way that PAK4 may protect cells from
apoptosis is by phosphorylating the proapoptotic protein Bad,
although unlike PAK1, PAK4 phosphorylates Bad specifically
on serine 112 (23). Consistent with this, we have found that
effector caspases such as caspase 3 are inhibited in response to
several stimuli in PAK4-expressing cells (23). Here we have
found, however, that in response to some types of stimuli,
notably ligation of TNF or Fas receptors, PAK4 inhibits apo-
ptosis by a mechanism that does not depend on its kinase
activity. Under these conditions, we have found that PAK4
inhibits apoptosis by inhibiting the activity of the initiator cas-
pase 8. PAK4 can thereby block the caspase cascade by acting
upstream of the mitochondrial pathway and effector caspases,
rather than by preventing phosphorylation of Bad and cyto-
chrome c release. This may be mediated in part by inhibition of
recruitment of caspase 8 to the death receptors.
MATERIALS AND METHODS
Cell culture and transfections. The HeLa pLPC and PAK4 cell lines (23) were
cultured at 37°C in 5% CO2 and maintained in Dulbecco’s modified Eagle’s
medium (Life Technologies) containing 10% fetal bovine serum (Life Technol-
ogies), 4 mM glutamine (Life Technologies), and 50 U of penicillin per ml and
50 g of streptomycin per ml (Cellgro), supplemented with 1 g of puromycin
per ml. NIH 3T3 pLPC, PAK4wt (55), and PAK4(K350 M) (PAK4KM) cells
were maintained in Dulbecco’s modified Eagle’s medium with glutamine and
antibiotics, containing 10% bovine calf serum (HyClone) and 2 g of puromycin
per ml. Before the experiments, cells were passaged and plated in medium
without puromycin. HeLa cells (2.7 million per 10-cm-diameter plates) were
transfected with Lipofectamine (Life Technologies) according to the manufac-
turer’s instructions. For serum deprivation experiments, cells were washed twice
in medium lacking serum and cultured for 24 h in the presence of 0.1, 0.5, or 10%
(complete medium) serum. Cells were harvested, fixed, stained with propidium
iodide, and analyzed by flow cytometry as described previously (23).
Generation of the PAK4K350 M HeLa and NIH 3T3 cell lines. NX and
BOSC packaging cell lines were transfected by the calcium phosphate method
with a retroviral vector plasmid containing a Myc-tagged PAK4K350M sequence
(pLPCmycPAK4KM [pNG81]). Viruses were collected and used to infect HeLa
or NIH 3T3 cells, respectively, and positive cells were selected with puromycin. Ex-
panded colonies were tested for the expression of the Myc tagged PAK4 protein
by Western blotting with Myc or PAK4 antibodies and by immunofluorescence.
Plasmids. pNG81 (pLPCmycPAK4K350M) was obtained by subcloning the
EcoRI-StuI fragment of the PAK4K350M sequence (1) in frame with the Myc
epitope tag sequence into the pCDNA3 vector and subsequently inserting it as
a HindIII-XhoI fragment in the pLPC vector. The chimeric receptor expres-
sion plasmid pCD120a/CD95, containing the extracellular domain of CD120a
(p55TNFR) and intracellular domain of CD95 (Fas), was described previously
(24). pCDNA3 was used as an empty vector or as buffering DNA for transient
transfections. pEBG was used as a control for transfection efficiency for the
expression of glutathione S-transferase (GST).
Reagents and antibodies. Recombinant human TNF- was purchased from
R&D Systems; cycloheximide (CHX) and other reagents were purchased from
Sigma unless otherwise stated. Monoclonal caspase 8 antibodies (clone 1C12),
rabbit polyclonal cleaved caspase 3 (D175), and human Bid were from Cell
Signaling; goat polyclonal TNFR1 antibodies were from R&D systems; mono-
clonal TNFR1 (H-5) and FLIPs/l (G11) antibodies were from Santa Cruz; mono-
clonal TRADD (clone 37), RIP (clone 38), and FADD (clone 1) were from BD
Transduction Labs; monoclonal poly(ADP-ribose) polymerase (PARP) (clone
4C10-5) antibodies were from PharMingen; monoclonal CD95 Fas antibodies (clone
CH-11) were from Immunotech; and monoclonal actin antibodies (clone AC-40)
were from Sigma. Monoclonal PAK4 antibodies were described previously (55).
Western blot analysis. Horseradish peroxidase-conjugated secondary antibod-
ies were from Sigma. Western blot protein bands were visualized by the ECL
method (Amersham). Stripping of antibodies from membranes after the ECL
reaction was performed according to the manufacturer’s instructions. Immo-
bilon-P–polyvinylidene difluoride membranes were from Millipore.
Analysis of TNFR and Fas signaling. For the analysis of endogenous proteins in
whole-cell lysates after TNF- or Fas stimulation, cells were stimulated and collected
as described previously (23) with 10 ng of TNF- per ml or 500 ng of Fas antibody
per ml, with or without 10 g of CHX per ml. Lysates were then prepared in M2
buffer supplemented with protease and phosphatase inhibitors, and equal amounts
of proteins were loaded on gels for sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) fractionation and Western blotting.
For the experiments involving coimmunoprecipitation of activated receptors,
protocols were adapted from those described previously (38, 77). For the analysis
of the endogenous TNFR1 signaling complex, 20 million cells were stimulated
with TNF- for the indicated times, rinsed in cold phosphate-buffered saline, and
lysed in 1 ml of Triton lysis buffer (TLB) (25 mM Tris [pH 7.6], 150 mM NaCl,
1% Triton X-100) supplemented with 10 g of aprotinin and leupeptin per ml,
1 mM Na3VO4, 1 mM EDTA, 30 mM NaF, 2 mM Na pyrophosphate, and 1 mM
phenylmethylsulfonyl fluoride for 1 h on ice. One-fiftieth of the clarified lysates
was saved and loaded as a control. The rest was added to 40 l of protein
G-agarose beads precoupled with 15 g of goat TNFR1 antibodies or goat serum
(Gibco) as a preimmune control and rotated overnight at 4°C. Immunoprecipi-
tates were washed twice with 1 ml of lysis buffer, twice with lysis buffer containing
0.5 M NaCl, and twice again with lysis buffer. Samples were denatured in sample
buffer and analyzed by SDS-PAGE and Western blotting.
For the analysis of the Fas signaling complex, cells were seeded in 10-cm-
diameter plates and transfected the next day with the indicated amounts of
pCD120a/CD95 DNA (24) and pCDNA plasmid, to a total of 15 g, with
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Lipofectamine. At 48 h after transfection, cells were stimulated with TNF- and
lysed with 600 l of TLB as described above. Immunoprecipitation was were
performed as described above, using 5 g of TNFR antibodies, with the following
washes: two washes in lysis buffer, two washes in high-salt buffer (TLB with 1 M
NaCl), one wash in lysis buffer, and two final washes in lysis buffer with the
detergent omitted.
RESULTS
PAK4 kinase activity is not required for protection from
TNF--induced apoptosis. Although PAK4 is widely expressed
during development, it is expressed at quite low levels in many
adult cells and tissues (1; J. Qu and A. Minden, unpublished
results). We have therefore been able to generate stable cell
lines which express PAK4 at levels that are higher than those
of endogenous PAK4 (Fig. 1). These cell lines provide a good
model system for studying the function of PAK4 in apoptosis
and survival. We have previously shown that overexpression of
PAK4 in different cell lines provides a survival advantage over
control cells following application of death-inducing stimuli,
protecting cells from undergoing apoptosis. To determine
whether PAK4’s ability to protect cells from apoptosis depends
FIG. 1. PAK4 kinase activity is not necessary for protection against death stimuli in HeLa cells. Stably transfected PAK4 protein was
overexpressed in HeLa and NIH 3T3 cell lines (A) pLPC or PAK4 (PAK4 refers to wild-type PAK4 in all of the figures) HeLa cell extracts were
probed with PAK4 antibodies to detect endogenous (PAK4) or stably transfected (hemagglutinin [HA]-PAK4) levels. (B) Expression of HA-tagged
wild-type PAK4 (HA-PAK4), Myc-tagged wild type PAK4, Myc-tagged PAK4KM (kinase dead) in HeLa or NIH 3T3 cell lines was detected as des-
cribed above. (C) Kinase-dead PAK4 cell lines are protected from TNF- induced apoptosis. HeLa control cells (pLPC) or HeLa cells expressing
wild-type (PAK4) or kinase-dead (PAK4KM) PAK4 were left unstimulated (un) or stimulated with 10 ng of TNF- per ml and 10 g of CHX per
ml for the indicated time in hours (TNF/CHX). Cells were collected, fixed, and stained with propidium iodide, and DNA content was analyzed
by flow cytometry. The percentage of cells displaying DNA content lower than the G1 peak (sub-G1%) is shown in the graph. (D) PAK4 kinase ac-
tivity is required for protection from serum deprivation-induced apoptosis in NIH 3T3 cell lines. NIH 3T3 control cells (pLPC) or cells expressing wild
type (PAK4) or kinase-dead (PAK4KM) PAK4 were cultured for 24 h in medium containing 10% (complete), 0.5%, or 0.1% serum. Cells were col-
lected, and apoptosis (sub-G1%) was analyzed by flow cytometry as described above. Data for one representative experiment of at least three in-
dependent ones are shown. (NIH 3T3 cells were used in these experiments because HeLa cells were resistant to serum deprivation-induced apoptosis.)
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on its kinase activity, stable cell lines containing empty vector,
wild-type PAK4, or kinase-dead PAK4 [PAK4(K350M)/
PAK4KM] were treated with death-inducing stimuli. As ex-
pected, after TNF- treatment of HeLa cells or serum depri-
vation of NIH 3T3 cells, the expression of wild-type PAK4
inhibited apoptosis under both conditions (23) (Fig. 1). Sur-
prisingly, however, although PAK4(K350M) did not protect
cells from serum deprivation-induced apoptosis, it was as effi-
cient as wild-type PAK4 in inhibiting TNF--induced apopto-
sis (Fig. 1). This suggests that at least in response to TNF-
stimulation, PAK4 may protect HeLa cells from undergoing
apoptosis by a mechanism that does not directly involve its
ability to phosphorylate substrates such as Bad.
TNF--induced activation of initiator caspase 8 and effector
caspase 3 is inhibited in PAK4-expressing cell lines. Since
PAK4 protects cells from TNF-induced apoptosis indepen-
dently of its kinase activity, and therefore presumably indepen-
dently of Bad phosphorylation, we were interested in deter-
mining what steps of the TNF-induced death pathway were
blocked by PAK4. One possibility is that PAK4 can affect
initiator caspases and thereby function upstream of, or inde-
pendently of, the mitochondrial pathway itself. To test this,
cleavage of the initiator caspase 8 and the effector caspase 3
was observed following TNF- treatment of the different stable
HeLa cell lines. Normally, engaging TNFR1 (also called p55
TNFR or CD120a) with TNF- in the presence of CHX causes
initiator pro-caspase 8 (a and b forms [p57/55]) to be processed
and cleaved into intermediate and active fragments (p43/41,
p20, p18, and p10). Active caspase 8 in turn can either activate
the mitochondrial pathway or cleave effector caspases such as
caspase 3. As expected, after 2 h of stimulation, considerable
amounts of intermediate and active caspase 8 fragments (p43/
41 and p18) could be detected in the control cells. By 4 h most
of the proenzyme had undergone processing, as detectable by
the decreased amount of full-length protein (Fig. 2). Effector
caspase 3 activation followed a similar time course, as judged
by the appearance of the active p17 fragment. In contrast, in
cells overexpressing PAK4, cleavage of both caspase 8 and
caspase 3 was dramatically reduced and delayed (Fig. 2). As
previously observed (23), the terminal apoptotic process is
actually delayed rather than completely blocked in PAK4 cells,
since caspase activation (see also Fig. 4) and DNA fragmen-
tation (not shown) eventually occur at the latest time points
but remain substantially lower than in control cells, indicating
that the onset of the apoptotic program is delayed. Thus,
following TNF- stimulation, not only was effector caspase 3
activation inhibited, but initiator caspase 8 was also affected.
This did not appear to be due to changes in the levels of
cellular Fas-associated death domain-like interleukin-1-con-
verting-enzyme-like inhibitory protein (cFLIP), which has
been shown to have a role in inhibiting caspase 8 activation in
T cells (34, 40, 61) (Fig. 2). These results suggest that the role
of PAK4 in inhibiting apoptosis by TNF- resides at the level
of initiator caspases.
PAK4-expressing cells are resistant to anti-FAS-induced apo-
ptosis. To determine whether PAK4 affects other death recep-
tor cascades in addition to the TNF- cascade, stable HeLa
cell lines were treated with anti-Fas receptor antibodies. Apo-
ptosis was then detected by observing cleavage of the effector
caspase substrate PARP (Fig. 3). In control cells, effector cas-
FIG. 2. Activation of both effector and initiator caspase is affected in PAK4 cell lines. HeLa control (pLPC) or PAK4 cells were left untreated
() or stimulated with 10 ng of TNF- per ml and 10 g of CHX per ml (), with TNF- alone (T), or with CHX alone (C) for the indicated
times in hours. Cells were harvested, and equal amounts of protein lysates were separated by SDS-PAGE, transferred to polyvinylidene difluoride
membranes, and probed with antibodies against caspase 8 (A and B), cleaved caspase 3 (C), or cFLIP (D). PAK4 expression levels and equal
loading of the samples were detected by probing the extracts with hemagglutinin (HA) (E) and actin (F) antibodies. Specific bands of caspase 8 a
and b proenzymes (proCaspase 8) and proteolytic products (p43/41), active p18 fragment, caspase 3 active p17 fragment, cFLIPshort, HA-PAK4,
and actin are indicated by arrows.
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pase activation (as judged by the appearance of the p85 PARP
cleavage product) was detected as early as 2 h after anti-FAS
stimulation in the presence of CHX, when more than 50% of
the PARP protein had been cleaved, as most of the cells had
started the apoptotic program. By 4 h the full-length p116
PARP protein was detectable only at very low levels, as most of
the protein had been cleaved. Conversely, when PAK4 cells
were treated with the same stimuli, caspase activation was
significantly delayed. After 2 h only a small portion of PARP
had been cleaved in the PAK4 cells, and at 4 h the full-length
p116 was still detectable. (Fig. 3). A similar delay in the acti-
vation of caspases was observed in kinase-dead PAK4 cells.
Importantly, as in the TNF--treated cells, caspase 8 cleavage
was also significantly impaired in the PAK4-containing Fas-
treated cells (Fig. 3). Thus, as with TNF--treated cells, Fas-
induced apoptosis and caspase 8 activation were reduced in the
presence of both wild-type and kinase-dead PAK4.
Suppression of Bid cleavage parallels caspase 8 inhibition
in PAK4-expressing cells. Although caspase 8 activation is
necessary for death receptor-induced apoptosis (39, 71), in
many cell types (also described as type II cells) the mitochon-
drial pathway is also required in order to induce full activation
of effector caspases and cell death (60). Cleavage and activa-
tion of the proapoptotic Bcl2 family member Bid (by initiator
caspase 8) was shown to be necessary for the activation of the
mitochondrial pathway by death receptors (29, 43, 45, 76). In
order to rule out the possibility that the small amount of
caspase 8 activity still present in PAK4 cells was still sufficient
to cause normal activation of this pathway, the caspase 8
substrate Bid was analyzed. When TNF--treated control cell
lysates were analyzed (Fig. 4D), the full-length Bid protein
decreased over time, and the cleavage product p15 was detect-
able as early as 2 h, coincident with the appearance of the
active caspase 8 fragment p18 (as well as the caspase 3 frag-
ment p17). In contrast, when PAK4-expressing cells were an-
alyzed, the level of full-length Bid remained high at the ana-
lyzed time points. Only a small amount of p15 was detectable
at the latest time point, and this coincided with a slight increase
in the caspase 8 p18 fragment and the caspase 3 p17 fragment
(Fig. 4). Similar results were obtained when anti-FAS-treated
cells were analyzed (Fig. 3C). Most importantly, they indicate
that the low level of caspase 8 seen in response to TNF- was
not sufficient to cause normal activation of the mitochondrial
pathway. These results lend further support to the hypothesis
that signaling by the death receptors TNFR1 and Fas is most
likely compromised at the level of caspase 8 activation in
PAK4-expressing cell lines.
TNF--induced association of TRADD and RIP with the
TNFR1 receptor is not inhibited by PAK4 expression. Upon
binding with their ligands, receptors of the TNF ligand family
trimerize and recruit a number of proteins through their pro-
tein-protein interaction motifs (2, 72), as described in the in-
troduction (Fig. 5, diagram). Given the defects in initiator
caspase activation in PAK4-expressing cells, we were interest-
ed in determining whether there were defects in the recruit-
ment of TNFR1-interacting proteins in the presence of PAK4.
FIG. 3. Stable cell lines expressing PAK4 are resistant to anti-FAS-induced apoptosis. HeLa control (pLPC) and wild-type (PAK4) or kinase-dead
(PAK4KM) PAK4 cells were left unstimulated (ns) or treated with 500 ng of anti-Fas per ml and 10 g of CHX per ml (F  C), for the indicated
time in hours. Cells were harvested, and equal amounts of protein lysates were separated by SDS-PAGE, transferred to polyvinylidene difluoride
membranes, and probed with antibodies against PARP (A), caspase 8 (B), or Bid (C). PAK4 expression levels and equal loading of the samples
were detected by probing the extracts with hemagglutinin (HA) and Myc antibodies (D) and actin antibodies (E). (Wild-type PAK4 is HA tagged,
and PAK4KM is Myc tagged). Specific bands of PARP full-length p116 protein or cleaved p85 product, caspase 8 a and b proenzymes (proCaspase
8) and proteolytic products (p43/41), active p18 fragment, active Bid p15 fragment (cleaved Bid), wild type HA-PAK4 or kinase dead myc-PAK4
(PAK4), and actin are indicated by arrows. An unspecific reactive band (us) migrating near to the p15 Bid fragment is indicated by an asterisk.
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Cells containing empty vector, wild-type PAK4, or kinase-dead
PAK4 were stimulated with TNF-, and lysates were collected
at different time points. After immunopurification of the
TNFR1, precipitates were analyzed by Western blotting for the
presence of the different interacting proteins (Fig. 5). After 5
min of stimulation, TNF--dependent binding of TRADD and
RIP to the p55 receptor could be detected. This interaction
decreased at a later time points (15 and 30 min). (Under these
conditions, it was not possible to detect the association of
FADD [Fig. 5D] or caspase 8 [not shown]). While in wild-type
PAK4 cells a lower recruitment of RIP was observed, this
defect was not detected in PAK4KM cells. Our results indicate
that expression of PAK4 had no major effect on recruitment of
TRADD and RIP to the TNFR.
Caspase 8 binding to the Fas DISC is partially blocked in
PAK4-expressing cells. Recruitment of FADD and caspase 8
to the endogenous TNFR1 could not be detected in the exper-
iment described above. In fact, in previous work, caspase 8
binding to TNFR1 could be detected only when the proteins
were overexpressed (6). Therefore, in order to analyze the
recruitment of FADD and caspase 8 to death domain recep-
tors, we evaluated their binding after activation of a trans-
fected Fas receptor. To visualize the Fas receptor DISC, cells
were transfected with a receptor that contains the extracellular
domain of CD120a (p55 TNFR1) and the intracellular domain
of CD95 (Fas/Apo-1) (24) (Fig. 6A). Control cells consistently
expressed only low levels of the transfected receptor, even
when large amounts of DNA were transfected. This was prob-
ably due to the fact that apoptosis occurred when high levels of
receptor were expressed (24). In contrast, when PAK4 cells
were transfected with the same amounts of receptor DNA,
high expression levels were obtained (Fig. 6A), even though
both cell types had equivalent transfection efficiencies (see
expression of GST, bottom panel of Fig. 6A). Therefore, in
order to compare DISC formation in the two cell lines, the
amount of receptor expression plasmid DNA was titrated in
order to obtain similar levels of the transfected receptor in
both cell types. Cells were then stimulated, and binding of the
DISC proteins was observed following receptor immunopre-
cipitation (Fig. 6B). The amount of FADD that was recruited
to the receptor appeared to be the same for both control and
PAK4 cells (Fig. 6B). However, the overall recruitment of
caspase 8 was diminished in PAK4-expressing cells, as illus-
trated by densitometry quantitation of the caspase 8 and re-
ceptor bands of the immunoprecipitates (Fig. 6C). Processing
of the small amount of caspase 8 protein that was present in
the complex was not inhibited, since the partially cleaved
precursors were detectable (Fig. 6B). Similar results were
obtained with PAK4KM cells, where high levels of trans-
fected receptor and lower caspase 8 recruitment were ob-
served (not shown). These data indicate that pro-caspase 8
recruitment at the Fas DISC is reduced in the presence of
excess PAK4.
FIG. 4. Cleavage of initiator caspase substrate Bid is affected in wild-type and kinase-dead PAK4 cell lines. HeLa control cells (pLPC) or cells
expressing wild-type PAK4 (PAK4) or two independent kinase-dead cell lines (PAK4KMcl3 and PAK4KMclE2) were left unstimulated () or
stimulated with 10 ng of TNF- per ml and 10 g of CHX per ml for the indicated times in hours (hs TNF/CHX). Cells were harvested, and equal
amounts of protein lysates were separated by SDS-PAGE, transferred to polyvinylidene difluoride membranes, and probed with antibodies against
caspase 8 (A and B), cleaved caspase 3 (B), or Bid (D). PAK4 expression levels and equal loading of the samples were detected by probing the
extracts with Myc (E), hemagglutinin (HA) (F), and actin (G) antibodies. Specific bands of caspase 8 a and b proenzymes (proCaspase 8) and
proteolytic products (p43/41), active p18 fragment, caspase 3 active p17 fragment, or Bid full-length protein or p15 active fragment (cleaved Bid),
wild-type HA-PAK4 or kinase-dead myc-PAK4, and actin are indicated by arrows. An unspecific reactive band (us) migrating near the p15 Bid
fragment is indicated by an asterisk.
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DISCUSSION
Since inhibition of apoptosis can lead to pathologies such as
cancer (28), it is extremely important to understand the mo-
lecular mechanism by which cells protect themselves from apo-
ptosis. Our previous studies indicate that PAK4 overexpression
protects cells from several different kinds of apoptotic stimuli
(23). While other PAKs can also promote cell survival, PAK4
appears to be most directly involved in the oncogenic process.
Unlike other PAKs, for example, PAK4 is highly transforming
in fibroblasts (55). Furthermore, while it is expressed at low
levels in most adult tissues, PAK4 is overexpressed in a wide
array of tumor cell lines (11). Our results raise the possibility
that the role of PAK4 in transformation may be mediated at
least in part by PAK4’s antiapoptotic role. It is therefore of
great interest to understand the mechanism by which PAK4
exerts its survival effects in cells.
One way that PAK4 may protect cells from apoptosis is by
phosphorylating the proapoptotic protein Bad (23), and other
PAK family members may operate by a similar mechanism (36,
62, 67, 74). However, we found that although in NIH 3T3
fibroblasts PAK4 kinase activity is required for, and correlates
with, the cell survival response following serum deprivation
(23), it is not required for protection from death receptor-
induced apoptosis in epithelial cells. This indicates that in
response to death receptor signals, PAK4 can operate by a
mechanism that does not depend on its kinase activity. This
effect was also evident in transient-transfection experiments,
where both wild-type and kinase-dead PAK4 expression plas-
mids conferred lower sensitivity to TNF-induced apoptosis
(not shown).
Although we previously showed that effector caspases are
inhibited in PAK4-expressing cells (23), here we have found
that in response to death receptors, the initiator caspase 8 is
also inhibited when PAK4 is overexpressed. Cleavage of the
caspase 8 substrate Bid is also inhibited in PAK4-expressing
cells, which further supports the idea that PAK4 functions at
the level of caspase 8. In HeLa cells after TNF/CHX treat-
ment, caspase 8 and Bid cleavage has also been shown to occur
FIG. 5. TNF--induced association of TRADD with the TNFR1 receptor is not inhibited by PAK4 expression. HeLa control (pLPC) or
wild-type (PAK4WT) or kinase dead (PAK4KM) PAK4 cells were left untreated (un) or stimulated with 10 ng of TNF- per ml for the indicated
times in minutes (min TNF-.). Cells were harvested, and equal volumes of protein lysates (WCL) were analyzed by Western blotting as described
below or used for immunopurification (Ip) (1/100 of total extracts) with goat antibodies against the extracellular domain of p55 TNFR (TNFR1)
or preimmune goat serum (goat immunoglobulin G [IgG]). Immunopurified complexes and whole-cell lysates were fractionated by SDS-PAGE,
transferred to polyvinylidene difluoride membranes, and probed with mouse antibodies against RIP (A and a), TNFR1 (B), TRADD (C and c),
or FADD (D and d). Specific bands are indicated by arrows on the right. Migration positions of IgG heavy (IgG H) and light (IgG L) chains are
also indicated. A diagram of TNFR-interacting proteins is also shown.
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FIG. 6. PAK4-expressing cells show decreased Fas DISC formation. (A) The transfected TNFR/Fas chimeric receptor in highly expressed in
PAK4 cell lines. HeLa control (pLPC) or wild-type PAK4 cells were transfected with empty vector () or the indicated amounts (in micrograms)
of TNFR/Fas chimeric receptor (pCD120a/CD95) or GST (pEBG) expression vector. After 48 h, cells were harvested and equal volumes of protein
lysates (1/100 of total extracts) (WCL) were analyzed by Western blotting as described below or used for immunopurification (Ip) with goat antibodies
against the extracellular domain of p55 TNFR (TNFR1) or preimmune goat serum (GS). Immunopurified complexes and whole-cell lysates were
fractionated by SDS-PAGE, transferred to polyvinylidene difluoride membranes, and probed with mouse antibodies against TNFR1 or GST. Spe-
cific bands are indicated by arrows on the right. Migration positions of the TNFR/Fas chimera are indicated by a brace. (B) Recruitment of caspase
8 is compromised in stable PAK4 cell lines. HeLa control (pLPC) or wild-type PAK4 cells were transfected with the indicated amounts (in mi-
crograms) of TNFR/Fas chimeric receptor (DNA pCD120a/CD95) expression vector. After 48 h, cells were left untreated () or stimulated with
10 ng of TNF- per ml for the indicated time in minutes and harvested. Equal volumes of protein lysates were analyzed by Western blotting as
described below or used for immunopurification (1/100 of total extracts) with goat antibodies against the extracellular domain of p55 TNFR or pre-
immune goat serum. Immunopurified complexes were fractionated by SDS-PAGE, transferred to polyvinylidene difluoride membranes, and probed with
mouse antibodies against caspase 8 or FADD. The blot probed with caspase 8 antibodies was stripped and reprobed with mouse antibodies against
TNFR1 to verify TNFR1 and TNFR/Fas expression levels (as indicated at the left of the middle panel). Specific bands are indicated by arrows on
the right. Migration positions of the TNFR/Fas chimera are indicated by a brace. Migration positions of IgG heavy and light chains are also indicated.
To verify equal loading, the lysates (WCL) were analyzed by Western blotting for PAK4 (HA-PAK4), full-length caspase 8 (proCaspase8), FADD,
and actin, as indicated. A diagram of the proteins interacting with the Fas intracellular domain of the TNFR/Fas chimeric receptor is also shown.
(C) Quantitation of the caspase 8 signal in the DISC shows reduced caspase 8 protein per amount of receptor in PAK4 cells. The pro-caspase 8 bands
of the top panel of panel B and the TNFR1 and TNFR/Fas bands (receptor) of the middle panel of panel B (pLPC and PAK4 lanes) were quantitated
by densitometry (NIH Image). The densities of pixels in equal areas were measured, and backgrounds (measured in the GS Ip lanes) were sub-
tracted. Receptor amounts for the single Ips were expressed as values relative to the amount of receptor present in the pLPC (ns) Ip lane. The relative
amount of caspase 8 pixels shown in the graph was obtained by dividing the measured value of caspase 8 by its relative receptor levels (relative
density of pixels). (The lowest relative value obtained [PAK4 ns lane] was similar to background levels and was set as the zero point of the y axis.)
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(with time courses similar to the ones we observed) under
conditions where the mitochondrial pathway is inhibited and
caspase 3 activation is not observed (54). In this perspective,
Bid cleavage thus occurs because it is a target for caspase 8,
and its cleavage cannot be explained by a possible feedback
loop. Taken together, these results suggest that PAK4 can
block apoptosis early in the caspase cascade.
We do not yet know how PAK4 inhibits caspase 8 activity.
However, we have ruled out the possibility that PAK4 func-
tions by causing changes in the protein levels of FLIP, which
can affect the activity of caspase 8 (13, 34, 40). Receptor acti-
vation also appeared to occur normally in the presence of
overexpressed PAK4. This was evident by a normal interaction
between TNFR1 and its binding protein TRADD in the
PAK4-expressing cells, as well as between the Fas receptor and
FADD. However, recruitment of caspase 8 (which binds via
FADD) to the Fas receptor was suppressed in the PAK4-
expressing cells. Processing to the intermediate (inactive) frag-
ments seemed to occur normally, but it has been shown that
partial processing is not sufficient to induce apoptosis (40, 70).
These data, together with the inefficient formation of the active
p18 fragment observed in cell lysates, indicate that the low
recruitment of caspase 8 that we observe in PAK4 cells is not
sufficient to induce full activation. We were not able to detect
caspase 8 recruitment to the activated endogenous TNFR1
receptor in any of the cell lines. This is most likely due to the
fact that this interaction, although well established, is observed
only when the proteins are ectopically overexpressed (6). We
expect that caspase 8 recruitment to the TNFR1 is also inhib-
ited by PAK4, however, since this recruitment is also mediated
by FADD. Furthermore, caspase 8 cleavage was similarly in-
hibited in both TNFR1- and Fas-stimulated cells.
The regulation of caspase 8 activity and recruitment is a
totally new function for PAK4, and our results suggest a novel
mechanism for PAK4 inhibition of apoptosis. Recently, cas-
pase 8 has also been implicated as a target for several other cell
survival proteins. For example, AKT, a survival protein and
target of the PI 3-kinase pathway, was previously been shown
to inhibit apoptosis by phosphorylating Bad as well as by acti-
vating the NF-B pathway (19, 46, 57, 67). Recently, however,
activated AKT has also been shown to inhibit caspase 8 acti-
vation, as well as its recruitment to the Fas DISC, and this is
thought to contribute to its role in protecting T cells from
Fas-induced apoptosis (37). PI 3-kinase, which can activate
AKT, was also recently shown to protect cells from apoptosis
by inhibiting caspase 8 activity. However, unlike in the previous
study, caspase 8 recruitment to the DISC was found to be
unaffected by PI 3-kinase. Instead, its processing seems to be
impaired via a mechanism that controls lateral diffusion and
aggregation of CD95 (69, 70). Other signaling proteins that
have recently been shown to protect cells from Fas-induced
apoptosis via inhibition of caspase 8 include protein kinase C
and MAP kinase (25, 30). In the case of protein kinase C,
recruitment of both FADD and caspase 8 to the receptor was
inhibited, while DISC assembly was unaffected in response to
MAP kinase. Thus, while Bad phosphorylation and the mito-
chondrial pathway have been considered to be primary targets
for several cell survival pathways, caspase 8 is emerging as a
new target for several important apoptosis inhibitors.
Our results indicate that PAK4 is one of the growing number
of cell survival proteins recently shown to inhibit apoptosis at
the level of caspase 8 activity. It will be interesting to determine
the molecular mechanism by which PAK4 inhibits caspase 8
activity and, possibly, recruitment to the DISC. One possibility
is that it operates by activating one of the pathways described
above. However, incubation with either MAP kinase inhibitors
or PI 3-kinase inhibitors did not affect PAK4’s ability to inhibit
caspase 8 activity and apoptosis (data not shown). Since a
kinase-inactive form of PAK4 can inhibit caspase 8 activity as
efficiently as wild-type PAK4 (Fig. 4), our results indicate that
PAK4 can operate a mechanism that does not depend on its
kinase activity. Interestingly, other members of the PAK family
have been shown to regulate some cellular functions, such as
cytoskeletal organization, independently of their kinase activity
(17, 64). It has been suggested, therefore, that PAKs operate
not only as protein kinases but also as scaffold proteins that
mediate important protein-protein interactions (3, 17). This
raises the possibility that PAK4 may bind to caspase 8 or other
components of the DISC and thereby directly inhibit recruit-
ment of caspase 8 to the receptor. Another possibility is that
PAK4 could control the recruitment of caspase 8 inhibitors or
could inhibit the dissociation of silencers of death domains.
In summary, we have found that PAK4 inhibits death do-
main-induced apoptosis by inhibiting the initiator caspase 8.
Similarly, recruitment of caspase 8 to death domain receptors
is also partially inhibited in PAK4-expressing cells. This is a
novel function for PAK4, and our results indicate that in ad-
dition to phosphorylating, on serine 112, the proapoptotic pro-
tein Bad (23), PAK4 can also function by inhibiting the activ-
ities of initiator caspases.
ACKNOWLEDGMENTS
This work was supported by a grant from the NIH (CA76342) and by
an American Scientist Development grant from the American Heart
Association to A.M.
REFERENCES
1. Abo, A., J. Qu, M. S. Cammarano, C. Dan, A. Fritsch, V. Baud, B. Belisle,
and A. Minden. 1998. PAK4, a novel effector for Cdc42Hs, is implicated in
the reorganization of the actin cytoskeleton and in the formation of filopo-
dia. EMBO J. 17:6527–6540.
2. Ashkenazi, A., and V. M. Dixit. 1998. Death receptors: signaling and mod-
ulation. Science 281:1305–1308.
3. Bagrodia, S., and R. A. Cerione. 1999. PAK to the future. Trends Cell Biol.
9:350–355.
4. Bagrodia, S., S. J. Taylor, C. L. Creasy, J. Chernoff, and R. A. Cerione. 1995.
Identification of a mouse p21Cdc42/Rac activated kinase. J. Biol. Chem.
270:22731–22737.
5. Beg, A. A., and D. Baltimore. 1996. An essential role for NF-kappaB in
preventing TNF-alpha-induced cell death. Science 274:782–784.
6. Boldin, M. P., T. M. Goncharov, Y. V. Goltsev, and D. Wallach. 1996.
Involvement of MACH, a novel MORT1/FADD-interacting protease, in
Fas/APO-1- and TNF receptor-induced cell death. Cell 85:803–815.
7. Boldin, M. P., E. E. Varfolomeev, Z. Pancer, I. L. Mett, J. H. Camonis, and
D. Wallach. 1995. A novel protein that interacts with the death domain of
Fas/APO1 contains a sequence motif related to the death domain. J. Biol.
Chem. 270:7795–7798.
8. Brown, J. L., L. Stowers, M. Baer, J. Trejo, S. Coughlin, and J. Chant. 1996.
Human Ste20 homologue hPAK1 links GTPases to the JNK MAP kinase
pathway. Curr. Biol. 6:598–605.
9. Budihardjo, I., H. Oliver, M. Lutter, X. Luo, and X. Wang. 1999. Biochem-
ical pathways of caspase activation during apoptosis. Annu. Rev. Cell Dev.
Biol. 15:269–290.
10. Burbelo, P. D., D. Drechsel, and A. Hall. 1995. A conserved binding motif
defines numerous candidate target proteins for both Cdc42 and Rac
GTPases. J. Biol. Chem. 270:29071–29074.
11. Callow, M. G., F. Clairvoyant, S. Zhu, B. Schryver, D. B. Whyte, J. R.
Bischoff, B. Jallal, and T. Smeal. 2002. Requirement for PAK4 in the an-
chorage-independent growth of human cancer cell lines. J. Biol. Chem.
277:550–558.
7846 GNESUTTA AND MINDEN MOL. CELL. BIOL.
12. Cantley, L. C. 2002. The phosphoinositide 3-kinase pathway. Science 296:
1655–1657.
13. Chang, D. W., Z. Xing, Y. Pan, A. Algeciras-Schimnich, B. C. Barnhart, S.
Yaish-Ohad, M. E. Peter, and X. Yang. 2002. c-FLIP(L) is a dual function
regulator for caspase-8 activation and CD95-mediated apoptosis. EMBO J.
21:3704–3714.
14. Chinnaiyan, A. M., K. O’Rourke, M. Tewari, and V. M. Dixit. 1995. FADD,
a novel death domain-containing protein, interacts with the death domain of
Fas and initiates apoptosis. Cell 81:505–512.
15. Dan, C., N. Nath, M. Liberto, and A. Minden. 2002. PAK5, a new brain-
specific kinase, promotes neurite outgrowth in N1E-115 cells. Mol. Cell.
Biol. 22:567–577.
16. Daniels, R. H., and G. M. Bokoch. 1999. p21-activated protein kinase: a
crucial component of morphological signaling? Trends Biochem. Sci. 24:
350–355.
17. Daniels, R. H., P. S. Hall, and G. M. Bokoch. 1998. Membrane targeting of
p21-activated kinase 1 (PAK1) induces neurite outgrowth from PC12 cells.
EMBO J. 17:754–764.
18. Datta, S. R., A. Brunet, and M. E. Greenberg. 1999. Cellular survival: a play
in three Akts. Genes Dev. 13:2905–2927.
19. Datta, S. R., H. Dudek, X. Tao, S. Masters, H. Fu, Y. Gotoh, and M. E.
Greenberg. 1997. Akt phosphorylation of BAD couples survival signals to the
cell-intrinsic death machinery. Cell 91:231–241.
20. Downward, J. 1999. How BAD phosphorylation is good for survival. Nat.
Cell Biol. 1:E33–E35.
21. Downward, J. 1998. Ras signalling and apoptosis. Curr. Opin. Genet. Dev.
8:49–54.
22. Foo, S. Y., and G. P. Nolan. 1999. NF-kappaB to the rescue: RELs, apoptosis
and cellular transformation. Trends Genet. 15:229–235.
23. Gnesutta, N., J. Qu, and A. G. Minden. 2001. The serine/threonine kinase
PAK4 prevents caspase activation and protects cells from apoptosis. J. Biol.
Chem. 276:14414–14419.
24. Goltsev, Y. V., A. V. Kovalenko, E. Arnold, E. E. Varfolomeev, V. M. Brodi-
anskii, and D. Wallach. 1997. CASH, a novel caspase homologue with death
effector domains. J. Biol. Chem. 272:19641–19644.
25. Gomez-Angelats, M., and J. A. Cidlowski. 2001. Protein kinase C regulates
FADD recruitment and death-inducing signaling complex formation in Fas/
CD95-induced apoptosis. J. Biol. Chem. 276:44944–44952.
26. Green, D., and G. Kroemer. 1998. The central executioners of apoptosis:
caspases or mitochondria? Trends Cell Biol. 8:267–271.
27. Green, D. R. 1998. Apoptotic pathways: the roads to ruin. Cell 94:695–698.
28. Green, D. R., and G. I. Evan. 2002. A matter of life and death. Cancer Cell
1:19–30.
29. Gross, A., X. M. Yin, K. Wang, M. C. Wei, J. Jockel, C. Milliman, H.
Erdjument-Bromage, P. Tempst, and S. J. Korsmeyer. 1999. Caspase
cleaved BID targets mitochondria and is required for cytochrome c release,
while BCL-XL prevents this release but not tumor necrosis factor-R1/Fas
death. J. Biol. Chem. 274:1156–1163.
30. Holmstrom, T. H., I. Schmitz, T. S. Soderstrom, M. Poukkula, V. L. Johnson,
S. C. Chow, P. H. Krammer, and J. E. Eriksson. 2000. MAPK/ERK signaling
in activated T cells inhibits CD95/Fas-mediated apoptosis downstream of
DISC assembly. EMBO J. 19:5418–5428.
31. Hsu, H., J. Huang, H. B. Shu, V. Baichwal, and D. V. Goeddel. 1996.
TNF-dependent recruitment of the protein kinase RIP to the TNF recep-
tor-1 signaling complex. Immunity 4:387–396.
32. Hsu, H., H. B. Shu, M. G. Pan, and D. V. Goeddel. 1996. TRADD-TRAF2
and TRADD-FADD interactions define two distinct TNF receptor 1 signal
transduction pathways. Cell 84:299–308.
33. Hsu, H., J. Xiong, and D. V. Goeddel. 1995. The TNF receptor 1-associated
protein TRADD signals cell death and NF-kappa B activation. Cell 81:495–
504.
34. Irmler, M., M. Thome, M. Hahne, P. Schneider, K. Hofmann, V. Steiner,
J. L. Bodmer, M. Schroter, K. Burns, C. Mattmann, D. Rimoldi, L. E.
French, and J. Tschopp. 1997. Inhibition of death receptor signals by cellular
FLIP. Nature 388:190–195.
35. Jaffer, Z. M., and J. Chernoff. 2002. p21-activated kinases: three more join
the Pak. Int. J. Biochem. Cell Biol. 34:713–717.
36. Jakobi, R., E. Moertl, and M. A. Koeppel. 2001. p21-activated protein kinase
gamma-PAK suppresses programmed cell death of BALB3T3 fibroblasts.
J. Biol. Chem. 276:16624–16634.
37. Jones, R. G., A. R. Elford, M. J. Parsons, L. Wu, C. M. Krawczyk, W. C. Yeh,
R. Hakem, R. Rottapel, J. R. Woodgett, and P. S. Ohashi. 2002. CD28-
dependent activation of protein kinase B/Akt blocks Fas-mediated apoptosis
by preventing death-inducing signaling complex assembly. J. Exp. Med. 196:
335–348.
38. Jones, S. J., E. C. Ledgerwood, J. B. Prins, J. Galbraith, D. R. Johnson, J. S.
Pober, and J. R. Bradley. 1999. TNF recruits TRADD to the plasma mem-
brane but not the trans-Golgi network, the principal subcellular location of
TNF-R1. J. Immunol. 162:1042–1048.
39. Juo, P., C. J. Kuo, J. Yuan, and J. Blenis. 1998. Essential requirement for
caspase-8/FLICE in the initiation of the Fas-induced apoptotic cascade.
Curr. Biol. 8:1001–1008.
40. Kirchhoff, S., W. W. Muller, A. Krueger, I. Schmitz, and P. H. Krammer.
2000. TCR-mediated up-regulation of c-FLIPshort correlates with resistance
toward CD95-mediated apoptosis by blocking death-inducing signaling com-
plex activity. J. Immunol. 165:6293–6300.
41. Kischkel, F. C., S. Hellbardt, I. Behrmann, M. Germer, M. Pawlita, P. H.
Krammer, and M. E. Peter. 1995. Cytotoxicity-dependent APO-1 (Fas/
CD95)-associated proteins form a death-inducing signaling complex (DISC)
with the receptor. EMBO J. 14:5579–5588.
42. Lee, N., H. MacDonald, C. Reinhard, R. Halenbeck, A. Roulston, T. Shi, and
L. T. Williams. 1997. Activation of hPAK65 by caspase cleavage induces
some of the morphological and biochemical changes of apoptosis. Proc. Natl.
Acad. Sci. USA 94:13642–13647.
43. Li, H., H. Zhu, C.-J. Xy, and J. Yuan. 1998. Cleavage of BID by caspase 8
mediates the mitochondrial damage in the fas pathway of apoptosis. Cell
94:491–501.
44. Liu, Z. G., H. Hsu, D. V. Goeddel, and M. Karin. 1996. Dissection of TNF
receptor 1 effector functions: JNK activation is not linked to apoptosis while
NF-kappaB activation prevents cell death. Cell 87:565–576.
45. Luo, L., I. Budihardjo, H. Zou, C. Slaughter, and X. Wang. 1998. Bid, a Bcl2
interacting protein, mediates cytochrome c release from mitochondria in
response to activation of cell surface death receptors. Cell 94:481–490.
46. Madrid, L. V., C. Y. Wang, D. C. Guttridge, A. J. Schottelius, A. S. Baldwin,
Jr., and M. W. Mayo. 2000. Akt suppresses apoptosis by stimulating the
transactivation potential of the RelA/p65 subunit of NF-kappaB. Mol. Cell.
Biol. 20:1626–1638.
47. Manser, E., T. Leung, H. Salihuddin, Z. S. Zhao, and L. Lim. 1994. A brain
serine/threonine protein kinase activated by Cdc42 and Rac1. Nature 367:
40–46.
48. Martin, G. A., G. Bollag, F. McCormick, and A. Abo. 1995. A novel serine
kinase activated by rac1/CDC42Hs-dependent autophosphorylation is re-
lated to PAK65 and STE20. EMBO J. 14:1970–1978.
49. Medema, J. P., C. Scaffidi, F. C. Kischkel, A. Shevchenko, M. Mann, P. H.
Krammer, and M. E. Peter. 1997. FLICE is activated by association with the
CD95 death-inducing signaling complex (DISC). EMBO J. 16:2794–2804.
50. Muzio, M., A. M. Chinnaiyan, F. C. Kischkel, K. O’Rourke, A. Shevchenko,
J. Ni, C. Scaffidi, J. D. Bretz, M. Zhang, R. Gentz, M. Mann, P. H. Krammer,
M. E. Peter, and V. M. Dixit. 1996. FLICE, a novel FADD-homologous
ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-
inducing signaling complex. Cell 85:817–827.
51. Muzio, M., B. R. Stockwell, H. R. Stennicke, G. S. Salvesen, and V. M. Dixit.
1998. An induced proximity model for caspase-8 activation. J. Biol. Chem.
273:2926–2930.
52. Nagata, S. 1997. Apoptosis by death factor. Cell 88:355–365.
53. Pandey, A., I. Dan, T. Z. Kristiansen, N. M. Watanabe, J. Voldby, E. Ka-
jikawa, R. Khosravi-Far, B. Blagoev, and M. Mann. 2002. Cloning and
characterization of PAK5, a novel member of mammalianp21-activated ki-
nase-II subfamily that is predominantly expressed in brain. Oncogene 21:
3939–3948.
54. Perez, D., and E. White. 2000. TNF-alpha signals apoptosis through a bid-
dependent conformational change in Bax that is inhibited by E1B 19K. Mol.
Cell 6:53–63.
55. Qu, J., M. S. Cammarano, Q. Shi, K. C. Ha, P. de Lanerolle, and A. Minden.
2001. Activated PAK4 regulates cell adhesion and anchorage-independent
growth. Mol. Cell. Biol. 21:3523–3533.
56. Raff, M. C. 1992. Social controls on cell survival and cell death. Nature
356:397–400.
57. Romashkova, J. A., and S. S. Makarov. 1999. NF-kappaB is a target of AKT
in anti-apoptotic PDGF signalling. Nature 401:86–90.
58. Rudel, T., and G. M. Bokoch. 1997. Membrane and morphological changes
in apoptotic cells regulated by caspase-mediated activation of PAK2. Science
276:1571–1574.
59. Salvesen, G. S., and V. M. Dixit. 1997. Caspases: intracellular signaling by
proteolysis. Cell 91:443–446.
60. Scaffidi, C., S. Fulda, A. Srinivasan, C. Friesen, F. Li, K. J. Tomaselli, K. M.
Debatin, P. H. Krammer, and M. E. Peter. 1998. Two CD95 (APO-1/Fas)
signaling pathways. EMBO J. 17:1675–1687.
61. Scaffidi, C., I. Schmitz, P. H. Krammer, and M. E. Peter. 1999. The role of
c-FLIP in modulation of CD95-induced apoptosis. J. Biol. Chem. 274:1541–
1548.
62. Schurmann, A., A. F. Mooney, L. C. Sanders, M. A. Sells, H. G. Wang, J. C.
Reed, and G. M. Bokoch. 2000. p21-activated kinase 1 phosphorylates the
death agonist bad and protects cells from apoptosis. Mol. Cell. Biol. 20:453–
461.
63. Sells, M. A., and J. Chernoff. 1997. Emerging from the Pak: the p21-activated
protein kinase family. Trends Cell Biol. 7:162–167.
64. Sells, M. A., U. G. Knaus, S. Bagrodia, D. M. Ambrose, G. M. Bokoch, and
J. Chernoff. 1997. Human p21-activated kinase (Pak1) regulates actin orga-
nization in mammalian cells. Curr. Biol. 7:202–210.
65. Shu, H. B., M. Takeuchi, and D. V. Goeddel. 1996. The tumor necrosis factor
receptor 2 signal transducers TRAF2 and c-IAP1 are components of the
tumor necrosis factor receptor 1 signaling complex. Proc. Natl. Acad. Sci.
USA 93:13973–13978.
VOL. 23, 2003 PAK4 INHIBITS CASPASE 8 ACTIVATION 7847
66. Stanger, B. Z., P. Leder, T. H. Lee, E. Kim, and B. Seed. 1995. RIP: a novel
protein containing a death domain that interacts with Fas/APO-1 (CD95) in
yeast and causes cell death. Cell 81:513–523.
67. Tang, Y., H. Zhou, A. Chen, R. N. Pittman, and J. Field. 2000. The Akt
proto-oncogene links Ras to Pak and cell survival signals. J. Biol. Chem.
275:9106–9109.
68. Thornberry, N. A., and Y. Lazebnik. 1998. Caspases: enemies within. Science
281:1312–1316.
69. Varadhachary, A. S., M. Edidin, A. M. Hanlon, M. E. Peter, P. H. Krammer,
and P. Salgame. 2001. Phosphatidylinositol 3-kinase blocks CD95 aggrega-
tion and caspase-8 cleavage at the death-inducing signaling complex by
modulating lateral diffusion of CD95. J. Immunol. 166:6564–6569.
70. Varadhachary, A. S., M. E. Peter, S. N. Perdow, P. H. Krammer, and P.
Salgame. 1999. Selective up-regulation of phosphatidylinositol 3-kinase ac-
tivity in Th2 cells inhibits caspase-8 cleavage at the death-inducing complex:
a mechanism for Th2 resistance from Fas-mediated apoptosis. J. Immunol.
163:4772–4779.
71. Varfolomeev, E. E., M. Schuchmann, V. Luria, N. Chiannilkulchai, J. S.
Beckmann, I. L. Mett, D. Rebrikov, V. M. Brodianski, O. C. Kemper, O.
Kollet, T. Lapidot, D. Soffer, T. Sobe, K. B. Avraham, T. Goncharov, H.
Holtmann, P. Lonai, and D. Wallach. 1998. Targeted disruption of the
mouse caspase 8 gene ablates cell death induction by the TNF receptors,
Fas/Apo1, and DR3 and is lethal prenatally. Immunity 9:267–276.
72. Wallach, D., E. E. Varfolomeev, N. L. Malinin, Y. V. Goltsev, A. V.
Kovalenko, and M. P. Boldin. 1999. Tumor necrosis factor receptor and Fas
signaling mechanisms. Annu. Rev. Immunol. 17:331–367.
73. Walter, B. N., Z. Huang, R. Jakobi, P. T. Tuazon, E. S. Alnemri, G. Litwack,
and J. A. Traugh. 1998. Cleavage and activation of p21-activated protein
kinase gamma-PAK by CPP32 (caspase 3). Effects of autophosphorylation
on activity. J. Biol. Chem. 273:28733–28739.
74. Wolf, D., V. Witte, B. Laffert, K. Blume, E. Stromer, S. Trapp, P. d’Aloja, A.
Schurmann, and A. S. Baur. 2001. HIV-1 Nef associated PAK and PI3-
kinases stimulate Akt-independent Bad-phosphorylation to induce anti-apo-
ptotic signals. Nat. Med. 7:1217–1224.
75. Yang, F., X. Li, M. Sharma, M. Zarnegar, B. Lim, and Z. Sun. 2001.
Androgen receptor specifically interacts with a novel p21-activated kinase,
PAK6. J. Biol. Chem. 276:15345–15353.
76. Yin, X. M., K. Wang, A. Gross, Y. Zhao, S. Zinkel, B. Klocke, K. A. Roth, and
S. J. Korsmeyer. 1999. Bid-deficient mice are resistant to Fas-induced hep-
atocellular apoptosis. Nature 400:886–891.
77. Zhang, S. Q., A. Kovalenko, G. Cantarella, and D. Wallach. 2000. Recruit-
ment of the IKK signalosome to the p55 TNF receptor: RIP and A20 bind
to NEMO (IKKgamma) upon receptor stimulation. Immunity 12:301–311.
7848 GNESUTTA AND MINDEN MOL. CELL. BIOL.
